Loading organizations...
§ Venture Capital · Amsterdam, Noord-Holland, The Netherlands
LSP Health Economics Fund, now operating under EQT Life Sciences, deploys capital into innovative health technologies. This investment strategy specifically targets companies developing advanced medical devices, diagnostics, and digital health solutions across Europe and North America. The fund focuses on technologies that enhance patient outcomes while simultaneously driving cost efficiencies within healthcare systems.
The investment strategy for the Health Economics funds originated over a decade ago under Life Sciences Partners (LSP) before its acquisition and rebranding to EQT Life Sciences. The first fund, LSP HEF 1, launched in 2012, followed by LSP HEF 2 in 2018. This approach was built on the insight that human ingenuity could address the growing pressures on healthcare systems through technologies offering both clinical and economic value.
The companies supported by LSP Health Economics Fund primarily serve patients and healthcare providers, addressing significant unmet medical needs in common diseases. The fund’s vision is to scale high-impact health technologies that deliver meaningful clinical and economic value. Investments aim to improve care quality and contribute to the long-term sustainability of global healthcare.
LSP Health Economics Fund has 2 tracked investments across 1 company. The latest tracked deal is $32.1M Series D in Vivasure Medical in March 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 13, 2023 | Vivasure Medical | $32.1M Series D | Haemonetics Corporation | Enterprise Ireland, European Investment Bank, Evonik Venture Capital, Fountain Healthcare Partners, Orchestra BioMed, Panakes Partners |
| May 17, 2022 | Vivasure Medical | $23.0M Series D | — | Evonik Venture Capital, Fountain Healthcare Partners, Orchestra BioMed, Panakes Partners |